Skyrizi vs. Ilumya
Are Skyrizi and Ilumya the Same Thing?
Skyrizi (risankizumab-rzaa) and Ilumya (tildrakizumab-asmn) injection are interleukin-23 antagonists used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Side effects of Skyrizi and Ilumya that are similar include upper respiratory infections and injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth, hives).
Side effects of Skyrizi that are different from Ilumya include headache, fatigue, and tinea infections (such as ringworm, athlete's foot, and jock itch).
Side effects of Ilumya that are different from Skyrizi include diarrhea.
Both Skyrizi and Ilumya may interact with "live" vaccines.
What Are Possible Side Effects of Skyrizi?
Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.
What Are Possible Side Effects of Ilumya?
Common side effects of Ilumya include
- upper respiratory infections,
- injection site reactions (hives, itching, pain, redness, inflammation, swelling, bruising, hematoma, and bleeding), and
- diarrhea
What Is Skyrizi?
Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
What Is Ilumya?
Ilumya (tildrakizumab-asmn) injection is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
What Drugs Interact With Skyrizi?
Skyrizi may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Skyrizi is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Skyrizi and for 4 weeks following completion of therapy. It is unknown if Skyrizi passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Skyrizi, and for 6 days after the last dose.
What Drugs Interact With Ilumya?
Ilumya may interact with live vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Ilumya; it is unknown how it would affect a fetus. It is unknown if Ilumya passes into breast milk. Consult your doctor before breastfeeding.
How Should Skyrizi be Taken?
The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.
How Should Ilumya be Taken?
The recommended dose of Ilumya is 100 mg at Weeks 0, 4, and every twelve weeks thereafter.